Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068

NIJEP Publications

NEWPORT INTERNATIONAL JOURNAL OF ENGINEERING AND PHYSICAL SCIENCES (NIJEP)

Volume 6 Issue 1 Page 43-48, 2026

https://doi.org/10.59298/NIJEP/2026/614348

Smart Nanoparticles for Precision Delivery of Anti-Inflammatory Agents in Obesity-Associated Metabolic Disorders

Mugabo Kalisa G.

Faculty of Engineering Kampala International University Uganda

ABSTRACT

Obesity-associated metabolic disorders, including insulin resistance, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease, are driven in large part by chronic low-grade inflammation. Conventional anti-inflammatory therapies often suffer from poor tissue specificity, limited bioavailability, and systemic side effects, which constrain their long-term clinical utility. Smart nanoparticles have emerged as advanced drug delivery platforms capable of precise, controlled, and stimuli-responsive delivery of anti-inflammatory agents to diseased metabolic tissues. These nanoparticles are engineered to sense pathological microenvironmental cues such as pH, oxidative stress, enzymatic activity, or inflammatory mediators, enabling site-specific drug release. This review provides a comprehensive overview of smart nanoparticle systems designed for the precision delivery of anti-inflammatory agents in obesity-associated metabolic disorders. We discuss the inflammatory mechanisms linking obesity to metabolic dysfunction, key design principles of smart nanoparticles, and current therapeutic strategies targeting adipose tissue, liver, and immune cells. Critical challenges related to safety, scalability, and clinical translation are examined, and emerging opportunities for next-generation nanomedicine approaches are highlighted. Collectively, smart nanoparticles represent a promising avenue for improving the efficacy and safety of anti-inflammatory therapies in metabolic disease management.

Keywords: smart nanoparticles; obesity; metabolic disorders; inflammation; targeted drug delivery

INTRODUCTION

Obesity has become a global epidemic with profound health and socioeconomic consequences. Beyond excessive fat accumulation, obesity is increasingly recognized as a chronic inflammatory condition that underlies a spectrum of metabolic disorders, including insulin resistance, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease[1–4]. These obesity-associated metabolic disorders are driven by persistent low-grade inflammation originating primarily from adipose tissue and propagated through systemic immune–metabolic crosstalk.

In obese individuals, adipose tissue undergoes extensive remodeling characterized by adipocyte hypertrophy, hypoxia, extracellular matrix deposition, and immune cell infiltration[5, 6]. This dysfunctional microenvironment promotes the activation of inflammatory signaling pathways and the release of pro-inflammatory cytokines and adipokines. Macrophages, T lymphocytes, and other immune cells accumulate in adipose tissue and contribute to sustained inflammation that interferes with insulin signaling and metabolic homeostasis. Inflammatory mediators released into circulation further impair liver, muscle, and pancreatic function, creating a feed-forward loop that exacerbates metabolic disease progression[7–11].

Current pharmacological approaches for managing obesity-associated metabolic disorders primarily focus on glycemic control, lipid lowering, or appetite regulation[12]. While these strategies can improve metabolic parameters, they often fail to directly address the underlying inflammatory pathology. Systemic anti-inflammatory drugs have been explored as adjunct therapies, but their clinical application is limited by poor tissue specificity, off-target immunosuppression, and adverse effects associated with chronic use. Consequently,

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068
NIJEP Publications

there is a pressing need for therapeutic platforms that can selectively deliver anti-inflammatory agents to inflamed metabolic tissues while minimizing systemic exposure[12–14].

Nanotechnology has introduced new possibilities for precision medicine in metabolic diseases. Nanoparticles can be engineered to encapsulate a wide range of therapeutic agents, protect them from degradation, and deliver them to specific tissues or cell types[15]. Among these platforms, smart nanoparticles represent a particularly promising class of nanocarriers. Unlike conventional nanoparticles, smart nanoparticles are designed to respond dynamically to pathological cues within the disease microenvironment, enabling controlled and on-demand drug release[16].

Smart nanoparticles can exploit characteristic features of obesity-associated inflammation, such as acidic pH, elevated reactive oxygen species, inflammatory enzymes, and altered redox states. By integrating stimuli-responsive elements into their design, these nanoparticles achieve higher therapeutic precision and reduced off-target toxicity[17, 18]. Additionally, advances in surface functionalization and biomimetic engineering have improved the ability of smart nanoparticles to target specific metabolic tissues, including adipose tissue and liver, as well as immune cells that orchestrate inflammation[17, 19].

Over the past decade, numerous preclinical studies have demonstrated the potential of smart nanoparticle-based delivery systems to enhance the efficacy of anti-inflammatory agents and improve metabolic outcomes in obesity models[20]. However, translation to clinical practice remains limited due to challenges related to safety, scalability, and regulatory approval. This review provides a detailed examination of smart nanoparticles for precision delivery of anti-inflammatory agents in obesity-associated metabolic disorders, highlighting mechanistic insights, technological advances, and future therapeutic opportunities.

2. Inflammatory Mechanisms in Obesity-Associated Metabolic Disorders

Chronic inflammation is a defining feature of obesity and a key driver of metabolic dysfunction. Adipose tissue inflammation arises as adipocytes expand beyond their vascular supply, leading to hypoxia and cellular stress[21]. Hypoxia-inducible factors activate transcriptional programs that promote inflammatory cytokine production and immune cell recruitment. Simultaneously, hypertrophic adipocytes exhibit increased lipolysis, releasing excess free fatty acids that activate pattern recognition receptors on immune cells[21, 22].

Macrophages are central mediators of obesity-associated inflammation. In lean adipose tissue, macrophages predominantly display an anti-inflammatory phenotype that supports tissue homeostasis[10, 23, 24]. Obesity induces a shift toward a pro-inflammatory phenotype characterized by the production of tumor necrosis factor-α, interleukin-6, and interleukin-1β. These cytokines impair insulin signaling in adipocytes and contribute to systemic insulin resistance. Crosstalk between macrophages and other immune cells, including T lymphocytes and B cells, further amplifies inflammatory signaling[10, 25].

Inflammation originating in adipose tissue extends to other metabolic organs. In the liver, inflammatory mediators promote hepatic insulin resistance, steatosis, and progression to non-alcoholic steatohepatitis[26]. In skeletal muscle, chronic inflammation disrupts glucose uptake and mitochondrial function. Pancreatic β-cells are also affected, as inflammatory cytokines impair insulin secretion and promote β-cell apoptosis[27]. These interconnected inflammatory processes underscore the need for therapeutic strategies that can target inflammation across multiple metabolic tissues[26, 28].

Importantly, the inflammatory microenvironment in obesity exhibits distinct biochemical and biophysical characteristics that can be exploited for targeted drug delivery. These features provide a rational basis for the development of smart nanoparticles capable of selectively releasing anti-inflammatory agents at sites of metabolic dysfunction[28].

3. Design Principles of Smart Nanoparticles

The effectiveness of smart nanoparticles depends on careful optimization of their physicochemical and biological properties. Particle size is a critical determinant of biodistribution, circulation time, and tissue penetration[29]. Nanoparticles in the range of 50–200 nm are generally optimal for prolonged circulation and accumulation in inflamed tissues with enhanced vascular permeability.

Material selection is equally important. Biodegradable polymers, lipid-based systems, and hybrid organic–inorganic nanoparticles are commonly used to ensure biocompatibility and controlled degradation[30]. Smart nanoparticles incorporate stimuli-responsive components that enable drug release in response to specific environmental cues. pH-responsive nanoparticles exploit the acidic microenvironment of inflamed tissues, while redox- and reactive oxygen species–responsive systems release their payload under oxidative stress conditions characteristic of obesity-associated inflammation[30].

Surface functionalization enhances targeting specificity and cellular uptake. Ligands such as peptides, antibodies, or small molecules can be attached to nanoparticle surfaces to recognize receptors overexpressed in metabolic tissues or immune cells[31, 32]. Biomimetic strategies, including coating nanoparticles with cell membranes or plasma proteins, further improve immune evasion and targeting efficiency. Collectively, these design principles enable smart nanoparticles to function as precision delivery systems that maximize therapeutic efficacy while minimizing systemic toxicity.

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068
NIJEP Publications

4. Smart Nanoparticle-Based Anti-Inflammatory Therapeutic Strategies

Smart nanoparticles have been employed to deliver a wide range of anti-inflammatory agents in obesity-associated metabolic disorders. Small-molecule drugs, including corticosteroids and non-steroidal anti-inflammatory agents, show enhanced efficacy and reduced side effects when encapsulated in nanoparticles that release their cargo selectively at inflamed sites[33, 34].

Natural anti-inflammatory compounds, such as curcumin and polyphenols, benefit particularly from nanoparticle-based delivery due to their poor solubility and bioavailability. Smart nanoparticles protect these compounds from degradation and enable controlled release within target tissues[35]. In addition, nanoparticles have been used to deliver nucleic acid-based therapeutics, including small interfering RNA and microRNA mimics, to silence pro-inflammatory genes or restore regulatory pathways[36].

Combination therapies represent a growing area of interest. Smart nanoparticles can co-encapsulate multiple agents, such as anti-inflammatory drugs and insulin sensitizers, allowing simultaneous modulation of inflammation and metabolic dysfunction. Stimuli-responsive release ensures that these agents are delivered in a coordinated and site-specific manner, enhancing therapeutic synergy.

5. Biological and Translational Challenges

Despite their promise, smart nanoparticle-based therapies face several biological and translational challenges. Off-target accumulation in organs such as the liver and spleen can limit delivery efficiency and raise safety concerns[37]. Inter-individual variability in obesity severity and inflammatory status further complicates treatment outcomes[37].

Long-term safety remains a critical consideration, particularly for chronic metabolic diseases requiring prolonged therapy. Potential immunogenicity, accumulation of non-degradable materials, and unintended immune modulation must be thoroughly evaluated[38]. From a translational perspective, large-scale manufacturing, reproducibility, and regulatory approval of complex smart nanoparticles pose significant hurdles. Addressing these challenges will require standardized testing protocols, robust preclinical models, and early integration of regulatory considerations into nanoparticle design.

6. Emerging Opportunities and Future Directions

Advances in nanotechnology, bioengineering, and computational modeling are driving the development of next-generation smart nanoparticles. Personalized nanomedicine approaches that tailor nanoparticle design to individual inflammatory and metabolic profiles hold promise for improving therapeutic outcomes[39]. Theranostic nanoparticles that combine diagnostic and therapeutic functions enable real-time monitoring of disease progression and treatment response[39].

Artificial intelligence and machine learning are increasingly being applied to optimize nanoparticle design and predict biological interactions. Additionally, emerging delivery routes, including localized and minimally invasive approaches, may further enhance targeting precision[40–42]. Integration of smart nanoparticle-based therapies with lifestyle interventions and existing pharmacological treatments could provide comprehensive solutions for metabolic disease management.

CONCLUSION

Smart nanoparticles represent a powerful platform for the precision delivery of anti-inflammatory agents in obesity-associated metabolic disorders. By exploiting pathological cues within inflamed tissues, these systems overcome key limitations of conventional therapies and enable targeted, controlled drug release. Preclinical evidence demonstrates significant potential for reducing inflammation and improving metabolic function. However, successful clinical translation will depend on addressing challenges related to safety, scalability, and regulatory approval. Continued interdisciplinary research and well-designed translational studies are essential for realizing the full potential of smart nanoparticles in combating obesity-driven metabolic disease.

REFERENCES

1. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
2. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
3. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
4. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
5. Uti, D.E., Omang, W.A., Alum, E.U., Bawa, I., Ugwu, O.P.-C., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068

6. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
7. Collins, K.H., Herzog, W., MacDonald, G.Z., Reimer, R.A., Rios, J.L., Smith, I.C., Zernicke, R.F., Hart, D.A.: Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity. Front. Physiol. 9, (2018). https://doi.org/10.3389/fphys.2018.00112
8. Fatima, I., Khan, A., Rahdar, A., Fathi-karkan, S., Kharaba, Z., Baino, F.: Optimized mesalamine-loaded polyelectrolyte complex nanoparticles for targeted colon delivery in inflammatory bowel disease treatment: A central composite design approach. Mater. 8, 100530 (2025). https://doi.org/10.1016/j.nxmate.2025.100530
9. da Cruz Nascimento, S.S., Carvalho de Queiroz, J.L., Fernandes de Medeiros, A., de França Nunes, A.C., Piuvezam, G., Lima Maciel, B.L., Souza Passos, T., Morais, A.H. de A.: Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review. PLoS ONE. 17, e0273942 (2022). https://doi.org/10.1371/journal.pone.0273942
10. Mussbacher, M., Derler, M., Basílio, J., Schmid, J.A.: NF-κB in monocytes and macrophages – an inflammatory master regulator in multitalented immune cells. Front. Immunol. 14, 1134661 (2023). https://doi.org/10.3389/fimmu.2023.1134661
11. Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
12. Hamooya, B.M., Siame, L., Muchaili, L., Masenga, S.K., Kirabo, A.: Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Front. Nutr. 12, (2025). https://doi.org/10.3389/fnut.2025.1661603
13. Umoru, G.U., David-Oku, E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
14. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
15. Umoru, G.U., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
16. Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., Cai, L.: Smart nanoparticles for cancer therapy. Signal Transduct. Target. Ther. 8, 418 (2023). https://doi.org/10.1038/s41392-023-01642-x
17. Yang, J., des Rieux, A., Malfanti, A.: Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 19, 15189–15219 (2025). https://doi.org/10.1021/acsnano.5c00700
18. Nwuruku, O.A., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
19. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, (2025). https://doi.org/10.3390/polym17081010
20. Zhang, H., Qi, X., Yang, L., Xia, P., Ling, J., Zheng, X., Liang, J., Yang, P., Chen, Y., Liu, X., Zhang, D., Rong, Y., Chen, C., Zhang, J., Yu, P., Gan, Y.: Advances in anthocyanin nanoparticle delivery systems in anti-inflammatory therapies. Pharmacol. Res. 222, 108038 (2025). https://doi.org/10.1016/j.phrs.2025.108038
21. Ouyang, J., Lu, W., Fan, Y., Jiang, Z., Du, Q., Liu, D., Ouyang, J., Lu, W., Fan, Y., Jiang, Z., Du, Q., Liu, D.: Adipose Tissue Metabolic Inflammation: A Key Driver of Cardiovascular Disease Pathogenesis and Underlying Mechanisms. IntechOpen (2025)
22. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
23. Brancewicz, J., Wójcik, N., Sarnowska, Z., Robak, J., Król, M.: The Multifaceted Role of Macrophages in Biology and Diseases. Int. J. Mol. Sci. 26, 2107 (2025). https://doi.org/10.3390/ijms26052107

24. Chen, S., Saeed, A.F.U.H., Liu, Q., Jiang, Q., Xu, H., Xiao, G.G., Rao, L., Duo, Y.: Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023). https://doi.org/10.1038/s41392-023-01452-1
25. Russo, L., Lumeng, C.N.: Properties and functions of adipose tissue macrophages in obesity. Immunology. 155, 407–417 (2018). https://doi.org/10.1111/imm.13002
26. Solleiro-Villavicencio, H., Viurcos-Sanabria, R., Aguayo-Guerrero, J.A., Pineda-Pérez, P.F., Méndez-García, L.A.: Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension. Front. Immunol. 16, 1620585 (2025). https://doi.org/10.3389/fimmu.2025.1620585
27. Alum, E., Aloh, H., Obasi, D., Okoroh, P., Aniokete, U., & Emeruwa, A. (2025). Maternal Nutrition, Toxicants, and Epigenetic Programming of Obesity Across Generations. Diabetes Metabolic Syndrome and Obesity, Volume 18, 4873-4911. https://doi.org/10.2147/dmso.s579409
28. Bansal, S., Vachher, M., Arora, T., Kumar, B., Burman, A.: Visceral fat: A key mediator of NAFLD development and progression. Hum. Nutr. Metab. 33, 200210 (2023). https://doi.org/10.1016/j.hnm.2023.200210
29. Kumar, M., Kulkarni, P., Liu, S., Chemuturi, N., Shah, D.K.: Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles. Adv. Drug Deliv. Rev. 194, 114708 (2023). https://doi.org/10.1016/j.addr.2023.114708
30. Sustainable and biocompatible hybrid materials-based sulfated polysaccharides for biomedical applications: a review. RSC Adv. 15, 4708–4767 (2025). https://doi.org/10.1039/d4ra07277d
31. Zheng, J., Sun, Y., Shen, Y., Zhou, Z.: Surface engineering of nanoparticles for precision medicine. Precis. Med. Eng. 2, 100037 (2025). https://doi.org/10.1016/j.preme.2025.100037
32. Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H.H.T., Duong, V.-A., Nguyen, H.V.: Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol. 6, (2024). https://doi.org/10.3389/fnano.2024.1456939
33. Guo, Z., Zhang, Y., Zhao, M., Zhang, W., Li, X., Zhou, F., Peng, H., Wang, Q., Chen, Z.: Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics. Mater. Today Bio. 34, 102220 (2025). https://doi.org/10.1016/j.mtbio.2025.102220
34. Koushki, K., Biswal, P., Vijay, G.V., Sadeghi, M., Dehnavi, S., Tra, N.T., Samala, S.K., Taba, M.Y., Vasan, A.B., Han, E., Mackeyev, Y., Krishnan, S.: Immunomodulatory Effects of Gold Nanoparticles: Impacts on Immune Cells and Mechanisms of Action. Nanomaterials. 15, (2025). https://doi.org/10.3390/nano15151201
35. Thiruvengadam, R., Kondapavuluri, B.K., Thangavelu, L., Thiruvengadam, M., Hatami, M., Kim, J.H.: Nanoparticle-based strategies with bioactive compounds for targeting oxidative stress in therapeutic interventions: A comprehensive review. Ind. Crops Prod. 227, 120804 (2025). https://doi.org/10.1016/j.indcrop.2025.120804
36. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V.M.M., Zingg, J.-M.: Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants. 13, 331 (2024). https://doi.org/10.3390/antiox13030331
37. Desai, N.: Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 14, 282–295 (2012). https://doi.org/10.1208/s12248-012-9339-4
38. Aljabali, A.A.A., Obeid, M.A., Gammoh, O., El-Tanani, M., Mishra, V., Mishra, Y., Kapre, S., Srivatsa Palakurthi, S., Hassan, Sk.S., Nawn, D., Lundstrom, K., Hromić-Jahjefendić, A., Serrano-Aroca, Á., Redwan, E.M., Uversky, V.N., Tambuwala, M.M.: Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions. Cancers. 16, 2030 (2024). https://doi.org/10.3390/cancers16112030
39. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
40. Ros, H., Chan, N., Cook, M.T., Shorthouse, D.: Artificial intelligence and machine learning guided optimization in drug delivery. Adv. Drug Deliv. Rev. 115781 (2026). https://doi.org/10.1016/j.addr.2026.115781
41. Hassan, Y.M., Wanas, A., Ali, A.A., El-Sayed, W.M.: Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases. J. Nanobiotechnology. 23, 668 (2025). https://doi.org/10.1186/s12951-025-03719-x
42. Jena, G.K., Patra, C.N., Jammula, S., Rana, R., Chand, S.: Artificial Intelligence and Machine Learning Implemented Drug Delivery Systems: A Paradigm Shift in the Pharmaceutical Industry. J. Bio-X Res. 07, 143–157 (2024). https://doi.org/10.34133/jbioxresearch.0016

Open Access
Online ISSN: 2992-5487
Print ISSN: 2992-6068

NIJEP Publications

CITE AS: Mugabo Kalisa G. (2026). Smart Nanoparticles for Precision Delivery of Anti-Inflammatory Agents in Obesity-Associated Metabolic Disorders. NEWPORT INTERNATIONAL JOURNAL OF ENGINEERING AND PHYSICAL SCIENCES,6(1): 43-48.
https://doi.org/10.59298/NIJEP/2026/614348